Key Highlights
- Shares of PBM skyrocketed by as much as 203.8% during trading on April 16, 2026, following reports that the White House intends to issue an executive order supporting ibogaine research initiatives.
- Psyence Biomedical broadened its clinical trial infrastructure in Australia, increasing from three locations to five sites for its ongoing NPX-5 Phase IIb psilocybin research.
- The biotech firm postponed its previously scheduled 1-for-6.25 reverse stock split, maintaining current share structure.
- Market observers characterize the rally as speculative momentum typical of micro-cap securities with limited liquidity rather than fundamental business developments.
- The company maintains a modest market capitalization of $11.63 million with a GF Score of 20/100 and profitability metrics at 1/10.
Psyence Biomedical (PBM) experienced extraordinary market activity on April 16, 2026. Shares surged beyond 200% as trading volumes spiked amid reports that the White House plans to issue an executive order advancing research into ibogaine, a psychedelic substance being investigated for PTSD treatment and various mental health applications.
According to Quiver PriceTracker, PBM concluded trading with gains of roughly 203.8%. GuruFocus data indicated intraday appreciation reached approximately 105.96% during earlier trading hours.
The anticipated White House directive represents a notable evolution in federal policy toward psychedelic-assisted therapies. Ibogaine has attracted attention from researchers exploring treatments for substance addiction and psychological trauma, and the executive action would encourage expanded scientific investigation.
While PBM’s core business centers on natural psilocybin rather than ibogaine specifically, the company benefited substantially from positive sentiment surrounding the broader psychedelics sector.
Australian Trial Network Expansion Provides Additional Catalyst
Beyond the regulatory headlines, PBM announced company-specific developments. The organization recently increased its Australian clinical trial infrastructure from three facilities to five locations. This expansion supports the advancement of Phase IIb trials for NPX-5, the company’s natural psilocybin therapeutic candidate designed for Adjustment Disorder in cancer patients undergoing palliative treatment.
The network expansion aims to accelerate patient enrollment and maintain dosing schedules throughout the research program. Official documentation was submitted to the SEC through a Form 6-K filing in April 2026.
No fresh clinical efficacy or safety results emerged on April 16. Market analysts characterized the price movement as momentum-based trading, with limited float amplifying volatility.
Additionally, the company announced it has delayed its previously disclosed 1-for-6.25 reverse stock split. Shares will continue trading on their current basis until management establishes a new implementation date. This decision maintained the existing share structure and likely contributed to the dramatic price action.
Financial Profile and Market Metrics
PBM operates as a micro-capitalization company with total market value of approximately $11.63 million. Prior to the surge, shares traded near $5.08—significantly below the 52-week peak of $74.94.
The company’s GF Score registers at 20 out of 100. While financial strength metrics score 8/10, profitability indicators remain weak at 1/10. The absence of a P/E ratio reflects ongoing losses.
Institutional ownership remains minimal. Throughout Q4 2025, five institutional investors reduced or eliminated their positions entirely. Parallel Advisors divested its complete stake of 151,250 shares. UBS Group represented the sole new institutional investor, acquiring 1,007 shares.
Insider transactions show no buying or selling activity over the preceding twelve months.
Psyence Biomedical operates a federally licensed psilocybin cultivation operation in Southern Africa and distributes products to international collaborators.
As of April 16, 2026, PBM generates no revenue and remains unprofitable while its clinical development programs continue through mid-stage evaluation.
